Your browser doesn't support javascript.
loading
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs.
Reggidori, Nicola; Bucci, Laura; Santi, Valentina; Stefanini, Benedetta; Lani, Lorenzo; Rampoldi, Davide; Ghittoni, Giorgia; Farinati, Fabio; Masotto, Alberto; Stefanini, Bernardo; Mega, Andrea; Biasini, Elisabetta; Foschi, Francesco Giuseppe; Svegliati-Baroni, Gianluca; Sangiovanni, Angelo; Campani, Claudia; Raimondo, Giovanni; Vidili, Gianpaolo; Gasbarrini, Antonio; Celsa, Ciro; Di Marco, Mariella; Giannini, Edoardo G; Sacco, Rodolfo; Brunetto, Maurizia Rossana; Azzaroli, Francesco; Magalotti, Donatella; Morisco, Filomena; Rapaccini, Gian Ludovico; Nardone, Gerardo; Vitale, Alessandro; Trevisani, Franco.
Afiliação
  • Reggidori N; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Bucci L; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Santi V; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Stefanini B; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Lani L; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Rampoldi D; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Ghittoni G; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Farinati F; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Masotto A; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Stefanini B; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Mega A; Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Biasini E; Unit of Semeiotics, Liver and Alcohol-Related Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Foschi FG; Gastroenterology Unit, Belcolle Hospital, Viterbo, Italy.
  • Svegliati-Baroni G; Department of Surgery, Oncology, and Gastroenterology, Gastroenterology Unit, University of Padova, Padua, Italy.
  • Sangiovanni A; Gastroenterology Unit, Ospedale Sacro Cuore Don Calabria, Negrar, Italy.
  • Campani C; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Raimondo G; Gastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy.
  • Vidili G; Infectious Diseases and Hepatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Gasbarrini A; Medicina Interna Faenza, Dipartimento Emergenza, Medicina Interna e Cardioloa IRCCS-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Meldola, AUSL Romagna, Meldola, Italy.
  • Celsa C; Liver Injury and Transplant Unit and Obesity Center, Polytechnic University of Marche, Ancona, Italy.
  • Di Marco M; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy.
  • Giannini EG; Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Florence, Italy.
  • Sacco R; Department of Clinical and Experimental Medicine, Division of Medicine and Hepatology, University of Messina, Messina, Italy.
  • Brunetto MR; Department of Medicine, Surgery and Pharmacy, AOU Sassari, Italy.
  • Azzaroli F; Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
  • Magalotti D; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
  • Morisco F; Medicina Ospedale Bolognini Seriate, ASST Bergamo Est, Italy.
  • Rapaccini GL; Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Nardone G; Gastroenterology Unit, IRCCS Ospedale San Martino, Genoa, Italy.
  • Vitale A; Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy.
  • Trevisani F; UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
JHEP Rep ; 5(8): 100784, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37520672
ABSTRACT
Background &

Aims:

Alcohol abuse and metabolic disorders are leading causes of hepatocellular carcinoma (HCC) worldwide. Alcohol-related aetiology is associated with a worse prognosis compared with viral agents, because of the lower percentage of patients diagnosed with HCC under routine surveillance and a higher burden of comorbidity in alcohol abusers. This study aimed to describe the evolving clinical scenario of alcohol-related HCC over 15 years (2006-2020) in Italy.

Methods:

Data from the Italian Liver Cancer (ITA.LI.CA) registry were used 1,391 patients were allocated to three groups based on the year of HCC diagnosis (2006-2010; 2011-2015; 2016-2020). Patient characteristics, HCC treatment, and overall survival were compared among groups. Survival predictors were also investigated.

Results:

Approximately 80% of alcohol-related HCCs were classified as cases of metabolic dysfunction-associated fatty liver disease. Throughout the quinquennia, <50% of HCCs were detected by surveillance programmes. The tumour burden at diagnosis was slightly reduced but not enough to change the distribution of the ITA.LI.CA cancer stages. Intra-arterial and targeted systemic therapies increased across quinquennia. A modest improvement in survival was observed in the last quinquennia, particularly after 12 months of patient observation. Cancer stage, HCC treatment, and presence of oesophageal varices were independent predictors of survival.

Conclusions:

In the past 15 years, modest improvements have been obtained in outcomes of alcohol-related HCC, attributed mainly to underuse of surveillance programmes and the consequent low amenability to curative treatments. Metabolic dysfunction-associated fatty liver disease is a widespread condition in alcohol abusers, but its presence did not show a pivotal prognostic role once HCC had developed. Instead, the presence of oesophageal varices, an independent poor prognosticator, should be considered in patient management and refining of prognostic systems. Impact and Implications Alcohol abuse is a leading and growing cause of hepatocellular carcinoma (HCC) worldwide and is associated with a worse prognosis compared with other aetiologies. We assessed the evolutionary landscape of alcohol-related HCC over 15 years in Italy. A high cumulative prevalence (78%) of metabolic dysfunction-associated fatty liver disease, with signs of metabolic dysfunction, was observed in HCC patients with unhealthy excessive alcohol consumption. The alcohol + metabolic dysfunction-associated fatty liver disease condition tended to progressively increase over time. A modest improvement in survival occurred over the study period, likely because of the persistent underuse of surveillance programmes and, consequently, the lack of improvement in the cancer stage at diagnosis and the patients' eligibility for curative treatments. Alongside the known prognostic factors for HCC (cancer stage and treatment), the presence of oesophageal varices was an independent predictor of poor survival, suggesting that this clinical feature should be carefully considered in patient management and should be included in prognostic systems/scores for HCC to improve their performance.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2023 Tipo de documento: Article